Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1S | P09871 | 5/20 | 0.42 |
| ▸ | F2 | P00734 | 3/20 | 0.40 |
| ▸ | F11 | P03951 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.38 |
| ▸ | KDR | P35968 | 6/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252626 | 0.91 | DHFR (0.39) | C1SPDGFRBKDRCSF1RDHFR | |
| Trifluoroacetic Acid SCHEMBL30467669 | 0.87 | F2 (0.40) | F2F11PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL30467704 | 0.86 | F2 (0.40) | F2F11PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL30467592 | 0.85 | F2 (0.40) | F2F11PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL30467564 | 0.84 | C1S (0.48) | C1SF2F11PRSS1PRSS2 | |
| SCHEMBL24252692 | 0.77 | DHFR (0.42) | PDGFRBKDRCSF1RDHFRLIPG | |
| SCHEMBL24252713 | 0.76 | DHFR (0.41) | PDGFRBKDRCSF1RDHFRLRRK2 | |
| SCHEMBL30467616 | 0.76 | DHFR (0.41) | PDGFRBKDRCSF1RDHFRLRRK2 | |
| Trifluoroacetic Acid SCHEMBL30467745 | 0.75 | F2 (0.35) | F2F11PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL30467715 | 0.75 | F2 (0.35) | F2F11PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | C1S 9/4885F2 125/4885F11 117/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | C1S 9/4885F2 125/4885F11 117/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | C1S 24/4885F2 1425/4885F11 195/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | C1S 13/4885F2 406/4885F11 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.